Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
Updated study well powered for primary endpoint with addition of fewer than 150 patients
Company targets completion of enrollment in mid-2023 and topline results in early 2024
Company to host live webcast today at 8:30 a.m. Eastern
Athira will host a live webcast to discuss the LIFT-AD interim analysis in greater detail at 8:30 a.m. Eastern Time today, Monday, Oct. 17, 2022. To access the live webcast, please visit https://us02web.zoom.us/webinar/register/WN_AtJ3jgG1RtmRRlcU_cYb-Q or the "Events and Presentations" page within the Investors section of the Athira website: https://investors.athira.com/news-and-events/events-and-presentations-investor. An archived replay will also be available on the website for at least 90 days following the event.
https://finance.yahoo.com/news/athira-pharma-advances-phase-2-110000499.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.